[关键词]
[摘要]
目的 探讨二至丸乙醇提取物对乳腺癌骨转移的预防作用及其对骨微环境的影响。方法 采用不同体积分数乙醇溶液回流提取二至丸,通过MTT实验比较50%、60%、70%、80%、90%乙醇提取物对4T1乳腺癌细胞活力的影响,采用划痕愈合实验和结晶紫染色评价二至丸乙醇提取物对4T1细胞迁移和增殖能力的影响;运用超高效液相色谱-四极杆-静电场轨道阱高分辨质谱联用(ultra-performance liquid chromatography-quadrupole/electrostatic field orbitrap high-resolution mass spectrometry,UPLC-Q-Exactive-MS/MS)分析二至丸乙醇提取物化学成分。经左心室注射萤火虫荧光素酶标记的4T1乳腺癌细胞(4T1-Luc)建立乳腺癌骨转移小鼠模型,设置对照组、模型组、顺铂(5 mg/kg)组和二至丸乙醇提取物高、低剂量(10、5 g/kg)组;利用小动物活体成像监测小鼠全身生物发光信号及体内肿瘤负荷变化,并记录小鼠生存状态、体质量变化及脏器指数;通过显微计算机断层扫描(micro-computed tomography,Micro-CT)评价骨微结构变化;ELISA检测血清中白细胞介素-6(interleukin-6,IL-6)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、γ干扰素(interferon-γ,IFN-γ)、骨保护素(osteoprotegerin,OPG)和核因子-κB受体活化因子配体(receptor activator of nuclear factor-κB ligand,RANKL)水平;苏木素-伊红(hematoxylin-eosin,HE)染色观察主要脏器和骨组织病理变化;抗酒石酸酸性磷酸酶(tartrate-resistant acid phosphatase,TRAP)染色观察破骨细胞相关表型变化。结果 不同体积分数乙醇提取物均可不同程度降低4T1细胞活力,其中70%乙醇提取物抑制作用最强,半数抑制浓度(half-maximal inhibitory concentration,IC50)为548.8 μg/mL,将其命名为E-EZP并用于后续研究。体外实验显示,E-EZP可降低4T1细胞划痕愈合率,减少结晶紫染色面积,抑制4T1细胞迁移和增殖(P<0.01、0.001)。UPLC-Q-Exactive-MS/MS共鉴定出E-EZP中27个化学成分,包括木犀草素、槲皮素、蟛蜞菊内酯、芹菜素-7-葡萄糖苷、异绿原酸A和异绿原酸C等。体内实验显示,与模型组比较,E-EZP组小鼠第21天双侧后肢骨ROI总光子通量降低(P<0.05、0.01),生存时间延长,体质量维持相对稳定,肝脏指数和脾脏指数降低(P<0.05、0.01、0.001);Micro-CT结果显示,E-EZP可改善模型小鼠骨微结构破坏和骨量丢失(P<0.05、0.01、0.001);ELISA结果显示,E-EZP可降低血清IL-6、TNF-α和RANKL水平(P<0.05、0.001),提高IFN-γ和OPG水平(P<0.001);组织病理学结果显示,E-EZP在实验剂量下未引起心、肝、肺、肾明显组织损伤,并可改善骨小梁结构,减少骨组织TRAP阳性细胞数量。结论 E-EZP可抑制4T1乳腺癌细胞增殖和迁移,降低乳腺癌骨转移模型小鼠骨骼区域肿瘤相关负荷,改善骨微结构及破骨细胞相关表型,其作用伴随血清炎症因子和RANKL/OPG水平变化,提示E-EZP具有抗肿瘤和保护骨微环境的双重作用。
[Key word]
[Abstract]
Objective To investigate the preventive effect of ethanol extract of Erzhi Pill (二至丸) on breast cancer bone metastasis and to explore its effect on the bone microenvironment. Methods Erzhi Pill was extracted by reflux extraction with ethanol solutions of different volume fractions. The effects of 50%, 60%, 70%, 80% and 90% ethanol extracts on the viability of 4T1 breast cancer cells were compared by MTT assay. The effects of ethanol extract of Erzhi Pill on 4T1 cell migration and proliferation were evaluated by wound healing assay and crystal violet staining. The chemical components of ethanol extract of Erzhi Pill were analyzed by ultra-performance liquid chromatography-quadrupole/electrostatic field orbitrap high-resolution mass spectrometry (UPLC-Q-Exactive-MS/MS). A mouse model of breast cancer bone metastasis was established by left ventricular injection of firefly luciferase-labeled 4T1 breast cancer cells (4T1-Luc). The mice were divided into control group, model group, cisplatin (5 mg/kg) group, ethanol extract of Erzhi Pill high-and low-dose (10, 5 g/kg) groups. In vivo imaging system was used to monitor bioluminescent signals and changes in tumor burden in mice. Survival status, body weight and organ indexes were recorded. Micro-computed tomography (Micro-CT) was used to evaluate bone microstructure. ELISA was used to detect the levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand (RANKL) in serum. Hematoxylin-eosin (HE) staining was used to observe pathological changes in major organs and bone tissues. Tartrate-resistant acid phosphatase (TRAP) staining was used to observe the phenotypic changes related to osteoclasts. Results The ethanol extracts at different concentrations reduced the viability of 4T1 cells to varying degrees. The 70% ethanol extract showed the strongest inhibitory effect, with a half-maximal inhibitory concentration (IC50) of 548.8 μg/mL. Therefore, this extract was named E-EZP and used in the following experiments. In vitro results showed that E-EZP reduced the wound healing rate and the crystal violet staining area of 4T1 cells, indicating that it inhibited cell migration and proliferation (P < 0.01, 0.001). UPLC-Q-Exactive-MS/MS analysis identified 27 chemical components in E-EZP, including luteolin, quercetin, wedelolactone, apigenin-7-glucoside, isochlorogenic acid A, and isochlorogenic acid C. In vivo results showed that, compared with model group, E-EZP decreased the total photon flux in the bilateral hindlimb bone ROIs on day 21 (P < 0.05, 0.01), prolonged survival time, maintained relatively stable body weight, and decreased the liver and spleen indexes (P < 0.05, 0.01, 0.001). Micro-CT results showed that E-EZP improved bone microstructural damage and bone loss in model mice (P < 0.05, 0.01, 0.001). ELISA results showed that E-EZP decreased the levels of IL-6, TNF-α and RANKL in serum (P < 0.05, 0.001), while increasing the levels of IFN-γ and OPG (P < 0.001). Histopathological results showed that E-EZP did not cause obvious damage to the heart, liver, lung or kidney at the tested doses. It also improved trabecular bone structure and reduced the number of TRAP-positive cells in bone tissue. Conclusion E-EZP inhibits the proliferation and migration of 4T1 breast cancer cells, reduces tumor-related burden in bone regions of mice with breast cancer bone metastasis models, and improves bone microstructure and osteoclast-related phenotypes. These effects are accompanied by changes in serum inflammatory factors and RANKL/OPG levels, indicating that E-EZP exerts dual roles in anti-tumor activity and protection of the bone microenvironment.
[中图分类号]
R285.5
[基金项目]
国家自然科学基金重点项目(82430123);国家自然科学基金面上项目(82676023); 国家自然科学基金区域创新发展联合基金重点支持项目(U25A20169); 山东省自然科学基金项目(ZR2025MS1285); 慢性非传染性疾病国家科技重大专项(SQ2024AAA030186); 山东省中医药科技项目(M20251705); 国家级领军人才项目(TP-001-2025)